Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells

Stock Information for Dyadic International Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Dyadic International Inc.

Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
Dyadic to Present at World Vaccine Congress | Washington
Dyadic Reports 2024 Year-End Financial Results and Business Updates
Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines
Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
Dyadic to Attend Multiple Industry Events in March
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.